Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
23 October, 2017 15:21 IST
Strides Shasun gets USFDA nod for Potassium Citrate ER tablets
Source: IRIS | 12 Sep, 2017, 10.15AM
Comments  |  Post Comment

Strides Shasun has received approval from the United States Food & Drug Administration (USFDA) for Potassium Citrate Extended-Release Tablets USP, 5 mEq, 10 mEq, and 15 mEq.

According to IMS data, the US market for Potassium Citrate is approximately USD 110 million.

The company will be the second generic player to commercialize the product. The product, which is the first approval for an Extended Release tablet for the company, will be launched immediately.

Potassium Citrate, a urinary alkalinizing agent, is used for preventing certain types of kidney stones. It works by neutralizing some of the acid in the urine, which helps reduce the formation of crystals. 

Shares of the company gained Rs 28.7, or 3.05%, to trade at Rs 970.00. The total volume of shares traded was 46,320 at the BSE (9.58 a.m., Tuesday).



Strides Shasun Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
BHEL bags order worth Rs 204 bn for Yadadri project - 23-Oct-2017 13:14
Ramco Systems sets up subsidiary in Indonesia - 23-Oct-2017 10:13
HCL Tech collaborates Volvo Ocean as IT services provider - 23-Oct-2017 10:08
Mahindra Lifespace partners with HDFC Capital for housing project - 23-Oct-2017 09:54
Suven Life Sciences secures product patent in Singapore - 18-Oct-2017 10:42
Wipro quarterly profit climbs 6% - 18-Oct-2017 10:24
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer